Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Carr A, Samaras K, Chisholm DJ, Cooper DA.
Lancet. 1998 Jun 20;351(9119):1881-3. doi: 10.1016/S0140-6736(98)03391-1.
Lipodystrophy associated with protease inhibitors.
Panse I, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E, Saiag P.
Br J Dermatol. 2000 Mar;142(3):496-500. doi: 10.1046/j.1365-2133.2000.03363.x.
Metabolic complications associated with HIV protease inhibitor therapy.
Nolan D.
Drugs. 2003;63(23):2555-74. doi: 10.2165/00003495-200363230-00001.
Protease inhibitor-associated angiolipomatosis.
Dank JP, Colven R.
J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):129-31. doi: 10.1016/s0190-9622(00)90021-5.
Protease inhibitor-induced lipodystrophy.
Williamson K, Reboli AC, Manders SM.
J Am Acad Dermatol. 1999 Apr;40(4):635-6. doi: 10.1016/s0190-9622(99)70452-4.
Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.
Tanaka T, Nakazawa H, Kuriyama N, Kaneki M.
Exp Ther Med. 2018 Feb;15(2):1314-1320. doi: 10.3892/etm.2017.5526. Epub 2017 Nov 17.
HIV protease inhibitor-related lipodystrophy syndrome.
Carr A.
Clin Infect Dis. 2000 Jun;30 Suppl 2:S135-42. doi: 10.1086/313854.
HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases.
Pujol RM, Domingo P, Xavier-Matias-Guiu, Francia E, Sanbeat MA, Alomar A, Vazquez G.
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):193-8. doi: 10.1016/S0190-9622(00)90125-7.
HIV-associated lipodystrophy syndrome.
Qaqish RB, Fisher E, Rublein J, Wohl DA.
Pharmacotherapy. 2000 Jan;20(1):13-22. doi: 10.1592/phco.20.1.13.34667.
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, Falloon J.
J Clin Endocrinol Metab. 1999 Jun;84(6):1925-31. doi: 10.1210/jcem.84.6.5740.
